PARP Inhibitors – Pipeline insights 2018

SKU: DMPI951 | Last Updated On: 2019-04-09 | Available Formats

PARP Inhibitors Pipeline Analysis

  • In recent years, drug discovery and design are focused on molecular targeting. Poly-ADP ribose polymerase (PARP) inhibitors are a targeted class of cancer drugs.
  • PARP is a cell protein that helps the damaged cells to self-repair. PARP inhibitors hold a potential to inhibit the repair of DNA damage in the cell and thus results in the accumulation of deleterious mutations leading to genetic instability.
  • Research studies have proved that fault in either of BRCA 1 and BRCA 2 genes have an elevated risk of some types of cancer.
  • Cells with the defect in one or both these genes are less likely to repair themselves. Blocking this protein with a PARP inhibitor showed impressive results in preventing the acceleration of cancer cells by intruding with their DNA repair mechanism and destroying them, thus resulting in a therapeutic outcome.
  • The PARP inhibitors are under development for the treatment of various types of cancer like ovarian cancer, breast cancer, lung cancer, prostate cancer, pancreatic cancer, and gastric cancer.
  • The efficacy of PARP inhibitors in cancer therapy is the subject of an increasing number of clinical trials in a variety of tumor types, including and beyond the expected BRCA mutation malignancies like exposure to UV light, radiation, certain anticancer drugs, or other substances in the environment.
  • Olaparib (Lynpraza), Clovis Oncology’s Rucaparib and Tesoro’s Zejula (Niraparib) are the 3 PARP inhibitors that have been approved for use in patients with suspected or confirmed BRCA-mutated advanced ovarian cancer. The biggest problem with hitting PARP seems to be anemia, so that will be worth focusing to differentiate itself out in clinical practice.
  • Clinical trials indicate that most of the studies are in early phase, phase 1, phase 2 stage of development. Drugs like Talazoparib of Pfizer, Veliparib of Abbvie, are in step 3 stage of development for treating different types of cancer that must increase the future market growth. BSI-401 of Sanofi, GPI 15427 of Eisai are in preclinical development.
  • Trends semblance that the cancer therapy market is reliably shifting from conventional therapeutics to modern therapeutics due to their enhanced safety, specificity and efficacy; thus, creating a fantastic opportunity for propitious therapeutics like PARP inhibitors.
  • The necessity for PARP inhibitors has grown exponentially with the increasing cases of cancer. Further, their enhanced productiveness in cancer treatment in combination with conventional therapeutics like chemotherapy and radiation therapy has been the reason for the exponential growth in the market, which is further strengthened by a robust and focused clinical pipeline. With several favorable factors facilitate the development path for success, PARP inhibitors can be expected to be one of the commanding cancer therapeutics of the future and are worth the focus.
Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest